搜索
Stoke Therapeutics Inc
STOK添加自选
30.080USD
-1.280-4.08%
收盘 05/15, 16:00（美东）报价延迟15分钟
1.87B总市值
亏损市盈率 TTM
查看详细走势图
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-4.08%
5天
-8.54%
1月
-14.88%
6月
+13.47%
今年开始到现在
-5.23%
1年
+208.20%
TradingKey Stoke Therapeutics Inc股票评分
单位: USD 更新时间: 2026-05-15操作建议
Stoke Therapeutics Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力稳定。当前估值合理，在生物技术与医疗研究行业排名50/382位。机构持股占比非常高，近一月多位分析师给出公司评级为强力买入。最高目标价45.10。中期看，股价处于下降通道。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Stoke Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Stoke Therapeutics Inc亮点
亮点风险
Stoke Therapeutics, Inc. is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with ribonucleic acid (RNA)-based medicines. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, zorevunersen (STK-002), is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The Company is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company’s initial focus is haploinsufficiency and diseases of the central nervous system and the eye.
业绩高增长
公司营业收入稳步增长，连续3年增长2000.46%
估值低估
公司最新PE估值-10.52，处于3年历史低位
机构减仓
最新机构持股73.67M股，环比减少7.37%
CI 精选加拿大股票基金持仓
明星投资者CI 精选加拿大股票基金持仓，最新持仓市值110.00
活跃度降低
近期活跃度降低，过去20天平均换手率-0.38
分析师目标
根据
12
位分析师
强力买入
评级
45.100
目标均价
+42.27%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Stoke Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Stoke Therapeutics Inc简介
Stoke Therapeutics, Inc. is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with ribonucleic acid (RNA)-based medicines. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, zorevunersen (STK-002), is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The Company is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company’s initial focus is haploinsufficiency and diseases of the central nervous system and the eye.
公司代码STOK
公司Stoke Therapeutics Inc
CEOSmith (Ian F)
网址https://www.stoketherapeutics.com/
相关品种
